Announcement with respect to the Resignation of Vinayaka Bodala, as Chief Financial Officer of the Company, with effect from 3rd April 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.6 pts more than Nifty Microcap 250 and 5.5 pts more than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indrayani Biotech's board met on April 3, 2025, with three key outcomes. First, the terms of its earlier-approved rights issue of up to Rs 49.90 Crores were changed from fully paid-up equity shares to partly paid-up equity shares, with a Rights Issue Committee formed to finalise details. Second, Chief Financial Officer Vinayaka Bodala resigned for personal reasons (resignation email dated March 1, 2025) and was relieved from April 3, 2025. Third, Dhinakaran Rajagopal was appointed as the new CFO from the same date. Dhinakaran has been with the company since 2021 as Chief Coordination Officer and brings 34 years of experience from Infosys, BHEL, and Indian Oil Corporation.
For shareholders, the partly paid-up structure of the rights issue means they may not need to pay the full amount upfront, reducing immediate cash outflow but adding uncertainty. The CFO change appears orderly with a qualified internal successor, so leadership continuity risk is low. The trading window remains closed until 48 hours after the March 31, 2025 quarterly results are declared.